PDS Biotechnology Co. (NASDAQ:PDSB) Sees Large Growth in Short Interest

PDS Biotechnology Co. (NASDAQ:PDSB) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 4,670,000 shares, a growth of 20.7% from the February 13th total of 3,870,000 shares. Based on an average trading volume of 630,100 shares, the short-interest ratio is currently 7.4 days. Approximately 13.8% of the shares of the company are sold short.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PDSB. Raymond James Financial Inc. acquired a new position in shares of PDS Biotechnology during the 4th quarter worth approximately $26,000. Jane Street Group LLC acquired a new position in shares of PDS Biotechnology during the 4th quarter worth approximately $58,000. Marshall Wace LLP increased its position in shares of PDS Biotechnology by 38.4% during the 4th quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock worth $64,000 after purchasing an additional 10,837 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of PDS Biotechnology during the 4th quarter worth approximately $89,000. Finally, Two Sigma Investments LP increased its position in shares of PDS Biotechnology by 273.5% during the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock worth $107,000 after purchasing an additional 48,132 shares during the last quarter. 26.84% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PDSB. B. Riley decreased their target price on PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, November 25th. HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price on shares of PDS Biotechnology in a report on Thursday, March 13th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.67.

PDS Biotechnology Trading Down 2.9 %

Shares of NASDAQ PDSB traded down $0.04 during midday trading on Wednesday, hitting $1.35. The stock had a trading volume of 463,266 shares, compared to its average volume of 568,126. The company’s 50-day simple moving average is $1.43 and its 200 day simple moving average is $2.24. The firm has a market cap of $51.56 million, a P/E ratio of -1.16 and a beta of 1.68. PDS Biotechnology has a fifty-two week low of $1.13 and a fifty-two week high of $5.00. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.